Polymorphic repeat in AIB1 does not alter breast cancer risk

[1]  G. Giles,et al.  Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. , 1999, Journal of the National Cancer Institute.

[2]  W. Willett,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.

[3]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.

[4]  P. Meltzer,et al.  In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[6]  A. Berchuck,et al.  Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.

[7]  G. Coetzee,et al.  Polymorphic exonic CAG microsatellites in the gene amplified in breast cancer (AIB1 gene) , 1998, Clinical genetics.

[8]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[9]  G. Giles,et al.  Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. , 1998, Journal of the National Cancer Institute.

[10]  A. Børresen-Dale,et al.  A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.

[11]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[12]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Coetzee,et al.  A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.

[14]  J. Manson,et al.  Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[16]  P. Kantoff,et al.  Amplified in breast cancer-1 glutamine repeat and prostate cancer risk , 2000 .

[17]  H. Li,et al.  Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. , 1998, Critical reviews in eukaryotic gene expression.

[18]  G. Secreto,et al.  ENDOGENOUS HORMONES AND BREAST CANCER , 1998 .

[19]  S L Zeger,et al.  Regression analysis for correlated data. , 1993, Annual review of public health.

[20]  L. Bernstein,et al.  Endogenous hormones and breast cancer risk. , 1993, Epidemiologic reviews.